n.a. (SNTS)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 67.14M
Div & Yield N.A. (N.A)
Santarus And Pharming Announce Submission Of RHUCIN Biologics License Application To FDA

Santarus And Pharming Announce Submission Of RHUCIN Biologics License Application To FDA

Specialty biopharmaceutical company Santarus, Inc. (NASDAQ: SNTS) and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced the submission of a Biologics License Application (BLA) to the U.

Santarus To Present At Piper Jaffray 22nd Annual Health Care Conference

Santarus To Present At Piper Jaffray 22nd Annual Health Care Conference

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus Announces Commercial Launch Of Novel Type 2 Diabetes Drug CYCLOSET

Santarus Announces Commercial Launch Of Novel Type 2 Diabetes Drug CYCLOSET

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced the commercial U.

Santarus CEO Discusses Q3 2010 Results – Earnings Call Transcript

Santarus CEO Discusses Q3 2010 Results – Earnings Call Transcript

Santarus CEO Discusses Q3 2010 Results â¿¿ Earnings Call Transcript

Santarus Reports Third Quarter 2010 Financial Results

Santarus Reports Third Quarter 2010 Financial Results

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended September 30, 2010.

Santarus Announces Positive Top-Line Results In E.U. Phase III Clinical Study Evaluating Budesonide MMX In Ulcerative Colitis

Santarus Announces Positive Top-Line Results In E.U. Phase III Clinical Study Evaluating Budesonide MMX In Ulcerative Colitis

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced positive top-line results from a second Phase III clinical study evaluating the safety and efficacy of budesonide MMX ® for the...

Cycloset Data To Be Presented In Poster Session At 8th Annual World Congress On Insulin Resistance, Diabetes & CVD

Santarus, Inc. (NASDAQ:SNTS) and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET ® (bromocriptine mesylate) tablets...

Santarus To Hold Third Quarter 2010 Financial Results Conference Call On November 8

Santarus To Hold Third Quarter 2010 Financial Results Conference Call On November 8

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it will release third quarter 2010 financial results after market close on Monday, November 8, 2010.

RHUCIN Clinical Trial Data Published In The Journal Of Allergy And Clinical Immunology

RHUCIN Clinical Trial Data Published In The Journal Of Allergy And Clinical Immunology

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced the publication of an integrated analysis of two randomized placebo-controlled clinical trials with RHUCIN ® (recombinant human...

Hypercom, YRC Worldwide: Volume Movers

Hypercom and YRC Worldwide were among stocks poised to move on above-average volume Thursday.

Santarus Adds Two Novel Biologic Drug Candidates To Pipeline

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, has expanded its development pipeline with the addition of two novel biologic drug candidates focused on specialty markets.

Santarus, Geron: Volume Movers

Several stocks trading below $5, including Santarus, were poised to move on above-average volume Thursday.

Santarus To Present At September Investment Conferences

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Fuqi Down on SEC Probe; Symantec Steady

Shares of Fuqi International dropped in extended trades after the company said it's the subject of a formal probe by the SEC, while Symantec built on gains in the regular session.

Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET

Santarus, Inc. (NASDAQ: SNTS), S2 Therapeutics, Inc.

Santarus Extends Maturity Of $25 Million Revolving Line Of Credit To July 2013

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it has extended the maturity date of its $25 million revolving line of credit with Comerica Bank from July 11, 2011 to July 11,...

Santarus Inc. Q2 2010 Earnings Call Transcript

Santarus Inc. Q2 2010 Earnings Call Transcript

Santarus Reports Second Quarter 2010 Financial Results

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended June 30, 2010.

Santarus To Present At BMO Capital Markets 10th Annual Focus On Healthcare Conference

Santarus To Present At BMO Capital Markets 10th Annual Focus On Healthcare Conference

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus To Hold Second Quarter 2010 Financial Results Conference Call On August 2

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it will release second quarter 2010 financial results after market close on Monday, August 2, 2010.

Santarus Announces Launch Of Prescription ZEGERID Authorized Generic And Company Restructuring

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that pursuant to its distribution and supply agreement with Prasco, LLC, Prasco is commencing shipments of an authorized generic of...

Santarus Begins Enrollment In Phase III Clinical Program For Rifamycin SV MMX In Travelers’ Diarrhea

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that is has begun to enroll patients in the first study in its Phase III clinical program to evaluate the efficacy and safety of ...

Santarus To Present At The Jefferies 2010 Global Life Sciences Conference

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Trico Marine Services, Sequenom: Early Volume Plays

Trico Marine Service was one of several stocks trading near $5 poised to move on above-average volume Friday.

Santarus Inc. Q1 2010 Earnings Call Transcript

Santarus Inc. Q1 2010 Earnings Call Transcript

Santarus Reports First Quarter 2010 Financial Results

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended March 31, 2010.

Santarus To Hold First Quarter 2010 Financial Results Conference Call On May 6

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that it will release first quarter 2010 financial results after market close on Thursday, May 6, 2010.

Dynavax, Santarus: Early Volume Plays

Dynavas and Santarus were among stocks trading near $5 were poised to move on above-average volume Thursday

Santarus Announces District Court Ruling In Par Litigation

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that the U.